ArticleFrontiers in neurology2025
Correlation of atorvastatin with subjective memory deficits: a study from the NHANES and FAERS databases.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners.Blood advances · 2026Review
- Association between atorvastatin and sarcopenia: a study based on NHANES and FAERS databases.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Atorvastatin-associated neurological adverse events: a disproportionality analysis with adjustment for confounding by indication.Frontiers in medicine · 2026Article
- Association between finasteride with subjective memory deficits: a study from the NHANES and FAERS databases.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-marketing regulatory data suggest a potential association between atorvastatin use and memory protection; however, findings from observational studies have been inconsistent and remain a subject of controversy. Objective: This study aims to investigate the correlation between atorvastatin exposure and subjective memory deficits, with the objective of providing more precise safety and efficacy information for its clinical use. Methods: We utilized two primary data sources: the National Health and Nutrition Examination Survey (NHANES) covering the years 2001 to 2018, and the Food and Drug Administration Adverse Event Reporting System (FAERS) spanning 2011 to 2018. We systematically analyzed the correlation between atorvastatin exposure and memory function using a range of statistical methods, including descriptive statistics, multivariate logistic regression, and receiver operating characteristic (ROC) curves. Results: In the analysis of the NHANES database, multivariate logistic regression modeling, after controlling for various factors such as demographic characteristics and lifestyle, revealed a significant association between atorvastatin use and a reduced risk of memory loss (OR = 0.47; 95% CI, 0.15-0.79; Conclusion: This study integrated data from NHANES and FAERS to provide a comprehensive analysis of the relationship between atorvastatin and memory function. On one hand, the NHANES findings support the potential benefits of atorvastatin in reducing the risk of memory loss. On the other hand, the FAERS data highlight specific cognitive side effects associated with the drug. Consequently, clinicians and patients should carefully consider both the potential benefits and risks of atorvastatin, taking into account individual patient differences and implementing appropriate monitoring strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.